Sionna Therapeutics (NASDAQ:SION) Releases Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Sionna Therapeutics (NASDAQ:SION) issued its quarterly earnings results on Monday. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.17), Zacks reports.

Sionna Therapeutics Stock Performance

Shares of NASDAQ SION opened at $12.32 on Monday. The company’s 50 day moving average price is $12.25. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $25.19.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SION. Stifel Nicolaus started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 target price on the stock. TD Cowen started coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a “buy” rating on the stock. Finally, Guggenheim started coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $45.00 price objective for the company.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.